What Has Been the Progress and Growth of the Blood Screening Market in Recent Years?
The blood screening market has seen considerable growth due to a variety of factors.
• In recent times, there has been a substantial growth in the size of the blood screening market. An increase from $3.15 billion in 2024 to $3.45 billion in 2025 with a Compound Annual Growth Rate (CAGR) of 9.6% is projected. The escalation during the historic period can be ascribed to the increased requirements for blood transfusions, escalation in transmissible diseases, government norms and regulations, growth in blood donations and collections, and concerns about global health and pandemics.
What Can Be Expected from the Blood Screening Market?
The Blood Screening market is expected to maintain its strong growth trajectory in upcoming years.
• The market for blood screening is set to experience swift expansion in the coming years. It is projected to reach a valuation of $5.37 billion by 2029, with a compound annual growth rate (CAGR) of 11.7%.
The predicted growth in this period is associated with enhancements in healthcare facilities, outreach programs for public health awareness, progression in the diagnostics of infectious diseases, and readiness to respond to pandemics and global health issues. The forecast period is likely to see trends such as an increase in infectious diseases, automation for greater efficiency, an escalation in the requirements for blood transfusion, focus on safety during transfusion, and pathogen detection research.
What Are the Critical Driver Fuelling The Blood Screening Market's Growth?
The escalating incidence of infectious diseases is projected to boost the growth of the blood screening market. Blood testing is frequently used to discover signs of illness by identifying a specific antibody produced against the pathogen, this greatly aids healthcare providers in managing infectious diseases and preventing further spreading of infection among patients and transmission from individual to individual. For example, as per the National Center for Biotechnology Information, a government agency in the United States, in June 2022, the incidence of infectious diseases in outpatient care has surged nearly threefold over the past two decades, rising from 8 to 26 per 1,000. Hence, the surge in infectious diseases' prevalence is fueling the expansion of the blood screening market.
How Is The Blood Screening Market segmented?
The blood screening market covered in this report is segmented –
1) By Product: Reagents And Kits, Instruments, Software And Services
2) By Technology: Nucleic Acid Testing, Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assays, Next-Generation Sequencing (NGS)
3) By End User: Blood Banks, Diagnostic Centers And Pathology Labs, Hospitals, Clinics, Ambulatory Surgical Centers (ASCs)
Subsegments:
1) By Reagents And Kits: Diagnostic Reagents, Testing Kits
2) By Instruments: Automated Analyzers, Manual Testing Equipment
3) By Software And Services: Laboratory Information Management Systems (LIMS), Data Analysis Software, Support And Consulting Services
Pre-Book The Blood Screening Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What New Trends Are Influencing The Blood Screening Market?
Major players in the blood screening market are creating technologies like liquid biopsy to promote early cancer detection, improve treatment monitoring, and facilitate personalized treatment methodologies. A liquid biopsy is a simple, non-invasive test that examines blood or other body fluids to identify cancer cells or genetic material from tumors. For example, in November 2023, Guardant Health, Inc., a biotechnology firm based in the US, introduced Shield blood-based screening tests. The Shield test investigates cell-free DNA (cfDNA) in the bloodstream, which may suggest the existence of colorectal tumors or precancerous growths. It specifically searches for changes in DNA fragments that are shed into the blood from cancer cells.
Who Are the Key Players In The Blood Screening Market?
Major companies operating in the blood screening market include:
• Abbott Laboratories
• Grifols S.A.
• Becton Dickinson and Company
• F. Hoffmann-La Roche AG
• bioMérieux S.A.
• Bio-Rad Laboratories Inc.
• Thermo Fisher Scientific Inc.
• Ortho Clinical Diagnostics Inc.
• Beckman Coulter Inc.
• Siemens Healthineers AG
• GE Healthcare
• DiaSorin S.p.A.
• Merck KGaA
• PerkinElmer Inc.
• Bio-Techne Corporation
• Roche Diagnostics GmbH
• Danaher Corporation
• Sysmex Corporation
• Natera Inc.
• GenMark Diagnostics Inc.
• QIAGEN N.V.
• Hologic Inc.
• Luminex Corporation
• Trinity Biotech plc
• Fujirebio Inc.
• OraSure Technologies Inc.
• Immunetics Inc.
• Accelerate Diagnostics Inc.
• Cepheid Inc.
• T2 Biosystems Inc.
• Haemonetics Corporation
• HTG Molecular Diagnostics Inc.
• Verax Biomedical Inc.
What Is The Most Dominant Region In The Blood Screening Market?
North America was the largest region in the blood screening market in 2024. The regions covered in the blood screening market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
